Product Information
LITHOSTAT 250 MG TABLET is a brand product labeled by Mission Pharmacal Company, priced at $6.6632 per EA under NDC 00178050001. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on May 31, 1983.
Strength
250 mg/1
Manufacturer
Mission Pharmacal CompanyNDC
00178050001
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETOHYDROXAMIC ACIDApproval Type
New Drug (NDA)
FDA Application
NDA018749FDA Approved
5/31/1983
On Market Since
5/31/1983
Pharmacological Classes
Price Statistics
The NADAC for LITHOSTAT 250 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 7.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.6632 per EA |
|---|---|
| All-time high | $7.1601 (Feb 11, 2026) |
| All-time low | $6.2283 (Apr 17, 2024) |
| 52-week high | $7.1601 |
| 52-week low | $6.5767 |
| Median price | $6.6729 |
| Average price | $6.7224 |
| Largest weekly change | -8.1% (Feb 18, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the acetohydroxamic acid market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mission Pharmacal Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
acetohydroxamic acid market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LITHOSTAT 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LITHOSTAT 250 MG TABLET, manufactured by Mission Pharmacal Company, is $6.6632 per EA (NDC 00178050001), effective Sep 30, 2026.
How has the price of LITHOSTAT 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for LITHOSTAT 250 MG TABLET has risen 7.0%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for LITHOSTAT 250 MG TABLET?
Since Apr 17, 2024, the NADAC for LITHOSTAT 250 MG TABLET has ranged from a low of $6.2283 (Apr 17, 2024) to a high of $7.1601 (Feb 11, 2026), with a median of $6.6729 per EA.
Are there cheaper alternatives to LITHOSTAT 250 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LITHOSTAT 250 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LITHOSTAT 250 MG TABLET?
LITHOSTAT 250 MG TABLET (NDC 00178050001) is labeled by Mission Pharmacal Company, and CMS classifies it as a brand product.